Veru Inc. (VERU) NASDAQ

0.48

-0.0087(-1.76%)

Updated at July 31 04:00PM

Currency In USD

Veru Inc.

Address

48 NW 25th Street

Miami, FL 33127

United States of America

Phone

305 509 6897

Sector

Healthcare

Industry

Biotechnology

Employees

210

First IPO Date

February 11, 1999

Key Executives

NameTitlePayYear Born
Dr. Mitchell S. Steiner F.A.C.S., M.D.Chairman, President & Chief Executive Officer1.46M1961
Mr. Martin TaylerExecutive Vice President of FC2 Global Operations180,5121969
Ms. Michele Greco CPAChief Financial Officer & Chief Administrative Officer493,7031959
Dr. Harry D. Fisch F.A.C.S., M.D.Vice Chairman & Chief Corporate Officer708,4461959
Dr. K. Gary Barnette Ph.D.Chief Scientific Officer862,5471968
Dr. Domingo Rodriguez M.D.Executive Vice President of Global Clinical Operations01962
Mr. Kevin J. Gilbert CPA, J.D.Executive Vice President of Corporate Development0N/A
Mr. Samuel FischExecutive Director of Investor Relations & Corporate Communications0N/A
Mr. Philip R. Greenberg J.D.Executive Vice President & Deputy General Counsel0N/A
Mr. Michael J. Purvis J.D.Executive Vice President, General Counsel & Corporate Strategy and Secretary0N/A

Description

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.